ECSP11011121A - Sales de fingolimod - Google Patents
Sales de fingolimodInfo
- Publication number
- ECSP11011121A ECSP11011121A EC2011011121A ECSP11011121A ECSP11011121A EC SP11011121 A ECSP11011121 A EC SP11011121A EC 2011011121 A EC2011011121 A EC 2011011121A EC SP11011121 A ECSP11011121 A EC SP11011121A EC SP11011121 A ECSP11011121 A EC SP11011121A
- Authority
- EC
- Ecuador
- Prior art keywords
- salts
- fingolimod
- fingolimod salts
- polymorphs
- hydrates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
- C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/08—Acetic acid
- C07C53/10—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/122—Propionic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/08—Malonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
- C07C59/08—Lactic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
- C07C63/04—Monocyclic monocarboxylic acids
- C07C63/06—Benzoic acid
- C07C63/08—Salts thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08168862 | 2008-11-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP11011121A true ECSP11011121A (es) | 2011-07-29 |
Family
ID=42062355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2011011121A ECSP11011121A (es) | 2008-11-11 | 2011-06-10 | Sales de fingolimod |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US8680146B2 (enExample) |
| EP (1) | EP2358660A2 (enExample) |
| JP (2) | JP2012508215A (enExample) |
| KR (1) | KR20110086142A (enExample) |
| CN (2) | CN102256933A (enExample) |
| AU (1) | AU2009315735B2 (enExample) |
| BR (1) | BRPI0921533A2 (enExample) |
| CA (1) | CA2741974A1 (enExample) |
| CL (1) | CL2011001041A1 (enExample) |
| CO (1) | CO6382154A2 (enExample) |
| EC (1) | ECSP11011121A (enExample) |
| IL (1) | IL212073A0 (enExample) |
| MA (1) | MA32877B1 (enExample) |
| MX (1) | MX2011004924A (enExample) |
| NZ (1) | NZ591999A (enExample) |
| PE (1) | PE20120012A1 (enExample) |
| RU (1) | RU2543621C2 (enExample) |
| TN (1) | TN2011000187A1 (enExample) |
| WO (1) | WO2010055027A2 (enExample) |
| ZA (1) | ZA201102272B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7973025B2 (en) | 2005-05-26 | 2011-07-05 | Neuron Systems, Inc. | Compositions and methods of treating retinal disease |
| CA2741974A1 (en) * | 2008-11-11 | 2010-05-20 | Novartis Ag | Salts of fingolimod |
| US8766005B2 (en) | 2009-07-24 | 2014-07-01 | Ratiopharm Gmbh | Process for producing fingolimod salts |
| WO2011072141A1 (en) | 2009-12-11 | 2011-06-16 | Neuron Systems, Inc. | Compositions and methods for the treatment of macular degeneration |
| CN103313964A (zh) | 2010-10-28 | 2013-09-18 | Mapi医药公司 | 用于制备芬戈莫德的中间化合物和方法 |
| WO2012071524A1 (en) | 2010-11-24 | 2012-05-31 | Ratiopharm Gmbh | Arylsulfonate salts of fingolimod and processes for preparation thereof |
| AR085749A1 (es) | 2011-04-01 | 2013-10-23 | Novartis Ag | Formulaciones |
| EP2505589A1 (en) | 2011-04-01 | 2012-10-03 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Novel sphingolipid heterocyclic compounds as modulators of sphingolipid signaling and uses thereof |
| CN102887829B (zh) * | 2012-09-05 | 2014-07-02 | 中国科学院上海药物研究所 | 芬戈莫德粘酸盐及其晶体的制备方法和用途 |
| SG11201505587YA (en) | 2013-01-23 | 2015-08-28 | Aldeyra Therapeutics Inc | Toxic aldehyde related diseases and treatment |
| JP6484567B2 (ja) | 2013-03-05 | 2019-03-13 | バイオコン・リミテッドＢｉｏｃｏｎ Ｌｉｍｉｔｅｄ | ２−アミノ−１，３−プロパンジオール化合物およびその塩の製造のための方法 |
| JP6401257B2 (ja) | 2013-10-11 | 2018-10-10 | テイコク ファーマ ユーエスエー インコーポレーテッド | 局所用スフィンゴシン−１−リン酸受容体アゴニスト製剤及びその使用方法 |
| WO2015053879A1 (en) | 2013-10-11 | 2015-04-16 | Teikoku Pharma Usa, Inc. | Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same |
| US9925138B2 (en) | 2015-01-20 | 2018-03-27 | Handa Pharmaceuticals, Llc | Stable solid fingolimod dosage forms |
| EP3247341A4 (en) * | 2015-01-20 | 2018-12-19 | Handa Pharmaceuticals, Llc | Stable solid fingolimod dosage forms |
| AU2016311158A1 (en) | 2015-08-21 | 2018-04-05 | Aldeyra Therapeutics, Inc. | Deuterated compounds and uses thereof |
| WO2017196881A1 (en) | 2016-05-09 | 2017-11-16 | Aldeyra Therapeutics, Inc. | Combination treatment of ocular inflammatory disorders and diseases |
| PL3466934T3 (pl) | 2016-05-31 | 2024-06-10 | Taiho Pharmaceutical Co., Ltd. | Związki sulfonoamidowe lub ich sól jako inhibitory reduktazy rybonukleotydowej do leczenia nowotworu |
| RU2627691C1 (ru) * | 2016-07-06 | 2017-08-10 | Олег Ростиславович Михайлов | Кристаллическая η-модификация 2-амино-2-(2-(4-октилфенил)этил)пропан-1,3-диол гидрохлорида, способ её получения и фармацевтическая композиция на её основе |
| MX2020003425A (es) | 2017-10-10 | 2020-07-29 | Aldeyra Therapeutics Inc | Tratamiento de trastornos inflamatorios. |
| MA51224A (fr) | 2017-11-29 | 2020-10-07 | Taiho Pharmaceutical Co Ltd | Composés de sulfonamide et leur utilisation |
| SG11202012787PA (en) * | 2018-06-29 | 2021-01-28 | Forma Therapeutics Inc | Salts of (s)-(5-cyclobutoxy-2-methyl-6-(1-(piperidin-4-yl)-1h-pyrazol-4-yl)-3,4-dihydroquinolin-1(2h)-yl)(cyclopropyl)methanone and solid forms thereof |
| EP3833660A4 (en) | 2018-08-06 | 2022-05-11 | Aldeyra Therapeutics, Inc. | POLYMORPHIC COMPOUNDS AND THEIR USES |
| JP2022530967A (ja) | 2019-05-02 | 2022-07-05 | アルデイラ セラピューティクス， インコーポレイテッド | 多形化合物およびその使用 |
| US12098132B2 (en) | 2019-05-02 | 2024-09-24 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| WO2021084068A1 (en) | 2019-10-31 | 2021-05-06 | Idorsia Pharmaceuticals Ltd | Combination of a cxcr7 antagonist with an s1p1 receptor modulator |
| CA3175856A1 (en) | 2020-05-13 | 2021-11-18 | Todd Brady | Pharmaceutical formulations and uses thereof |
| EP4353709A4 (en) * | 2021-05-31 | 2026-02-18 | Shanghai Yonsun Biotechnology Co Ltd | FINGOLIMOD PHARMACEUTICAL SALT, ITS PREPARATION PROCESS, PHARMACEUTICAL COMPOSITION, CONTAINER AND ASSOCIATED USES |
| EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994008943A1 (fr) | 1992-10-21 | 1994-04-28 | Yoshitomi Pharmaceutical Industries, Ltd. | Compose 2-amino-1,3-propanediol et immunosuppresseur |
| ECSP951461A (es) | 1995-06-07 | 1998-04-07 | SINTESIS DE 3- {4-(2- AMINOETOXI) BENZOIL]-2-ARIL-6- HIDROXIBENZO {b] TIOFENOS (CASO X- 9295B) | |
| ECSP972265A (es) | 1997-09-23 | 1998-11-30 | Dihidrato de d-olanzapina | |
| FR2785607B1 (fr) | 1998-11-09 | 2001-02-09 | Rhodia Chimie Sa | Procede de preparation de tris(ether-amine) |
| ES2237970T3 (es) * | 1998-11-11 | 2005-08-01 | Novartis Ag | Produccion de 2-amino-2-(2-(4-alquil c2-20-fenil)etil)propano-1,3-dioles. |
| JP4627356B2 (ja) * | 1999-06-30 | 2011-02-09 | 昭 松森 | ウイルス性心筋炎の予防または治療薬剤 |
| JP4476623B2 (ja) * | 2001-06-08 | 2010-06-09 | ノバルティス アーゲー | インスリン産生細胞移植片拒絶の処置または予防 |
| NZ560662A (en) | 2002-05-16 | 2009-09-25 | Novartis Ag | Use of EDG receptor binding agents in cancer |
| GB0217152D0 (en) * | 2002-07-24 | 2002-09-04 | Novartis Ag | Organic compounds |
| BRPI0409250B8 (pt) | 2003-04-08 | 2022-01-18 | Mitsubishi Pharma Corp | Composições farmacêuticas sólidas compreendendo um agonista receptor de s1p e um álcool do açúcar |
| GT200600350A (es) | 2005-08-09 | 2007-03-28 | Formulaciones líquidas | |
| CA2623826A1 (en) * | 2005-09-30 | 2007-04-12 | Novartis Ag | Dpp iv inhibitor for use in the treatment of autoimmune diseases and graft rejection |
| EP2046315B1 (en) | 2006-06-02 | 2013-04-10 | The Ohio State University Research Foundation | Therapeutic agents for the treatment of mantle cell lymphoma |
| US7985586B2 (en) * | 2008-02-04 | 2011-07-26 | Georgia Health Sciences University | Oligodendrocyte precursor cell composition and methods of use |
| CA2741974A1 (en) * | 2008-11-11 | 2010-05-20 | Novartis Ag | Salts of fingolimod |
-
2009
- 2009-11-10 CA CA2741974A patent/CA2741974A1/en not_active Abandoned
- 2009-11-10 WO PCT/EP2009/064889 patent/WO2010055027A2/en not_active Ceased
- 2009-11-10 AU AU2009315735A patent/AU2009315735B2/en not_active Ceased
- 2009-11-10 KR KR1020117013304A patent/KR20110086142A/ko not_active Ceased
- 2009-11-10 EP EP09752168A patent/EP2358660A2/en not_active Withdrawn
- 2009-11-10 RU RU2011123365/04A patent/RU2543621C2/ru not_active IP Right Cessation
- 2009-11-10 BR BRPI0921533A patent/BRPI0921533A2/pt not_active IP Right Cessation
- 2009-11-10 CN CN2009801448205A patent/CN102256933A/zh active Pending
- 2009-11-10 PE PE2011000987A patent/PE20120012A1/es not_active Application Discontinuation
- 2009-11-10 MX MX2011004924A patent/MX2011004924A/es active IP Right Grant
- 2009-11-10 CN CN201510547567.5A patent/CN105198760A/zh active Pending
- 2009-11-10 US US13/128,832 patent/US8680146B2/en not_active Expired - Fee Related
- 2009-11-10 JP JP2011535129A patent/JP2012508215A/ja not_active Withdrawn
- 2009-11-10 NZ NZ591999A patent/NZ591999A/xx not_active IP Right Cessation
-
2011
- 2011-03-28 ZA ZA2011/02272A patent/ZA201102272B/en unknown
- 2011-03-31 IL IL212073A patent/IL212073A0/en unknown
- 2011-04-19 TN TN2011000187A patent/TN2011000187A1/fr unknown
- 2011-05-10 CL CL2011001041A patent/CL2011001041A1/es unknown
- 2011-05-12 CO CO11058592A patent/CO6382154A2/es not_active Application Discontinuation
- 2011-06-03 MA MA33910A patent/MA32877B1/fr unknown
- 2011-06-10 EC EC2011011121A patent/ECSP11011121A/es unknown
-
2014
- 2014-02-13 US US14/179,807 patent/US20140235722A1/en not_active Abandoned
-
2015
- 2015-04-24 JP JP2015089480A patent/JP2015178503A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009315735B2 (en) | 2013-01-10 |
| KR20110086142A (ko) | 2011-07-27 |
| BRPI0921533A2 (pt) | 2016-01-12 |
| US20110218248A1 (en) | 2011-09-08 |
| AU2009315735A1 (en) | 2010-05-20 |
| CN102256933A (zh) | 2011-11-23 |
| ZA201102272B (en) | 2011-12-28 |
| MA32877B1 (fr) | 2011-12-01 |
| PE20120012A1 (es) | 2012-02-02 |
| JP2015178503A (ja) | 2015-10-08 |
| CN105198760A (zh) | 2015-12-30 |
| TN2011000187A1 (en) | 2012-12-17 |
| IL212073A0 (en) | 2011-06-30 |
| WO2010055027A3 (en) | 2010-08-19 |
| MX2011004924A (es) | 2011-05-30 |
| US8680146B2 (en) | 2014-03-25 |
| CL2011001041A1 (es) | 2011-10-07 |
| RU2011123365A (ru) | 2012-12-20 |
| US20140235722A1 (en) | 2014-08-21 |
| JP2012508215A (ja) | 2012-04-05 |
| NZ591999A (en) | 2013-06-28 |
| EP2358660A2 (en) | 2011-08-24 |
| WO2010055027A2 (en) | 2010-05-20 |
| CA2741974A1 (en) | 2010-05-20 |
| RU2543621C2 (ru) | 2015-03-10 |
| CO6382154A2 (es) | 2012-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP11011121A (es) | Sales de fingolimod | |
| CR11420A (es) | Moduladores de gpr40 bifenilo sustituidos | |
| CL2012003009A1 (es) | Acido3-(((3-butil-3-etil-(metiloxi)-1-1-dioxido-5-fenil-2,3,4,5-tetrahidro-1,4benxotiazepin-8-il)-metil)-amino)-pentanodioco; composicion farmaceutica que lo comprende; y su uso en un tastorno metabolico. pct. | |
| AR071812A1 (es) | Composicion tonalizadora | |
| CY1120389T1 (el) | Φαρμακευτικη συνθεση που περιλαμβανει εναν glp-1-αγωνιστη, μια ινσουλινη και μεθειονινη | |
| UY33317A (es) | Nuevos derivados de pirazol | |
| CU20110109A7 (es) | Nueva composición a base de ácido gamma-hidroxibutírico | |
| DOP2010000084A (es) | Derivado de uracilo o timina para el tratamiento de hepatitis c | |
| GT200500242A (es) | Procesos para la preparaciòn de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas | |
| SMT201400179B (it) | 1,2,5-Ossadiazoli come inibitori di indoleamina 2,3-diossigenasi | |
| BR112013012971A8 (pt) | Microagulhas de polímero cristalino líquido | |
| AR077047A1 (es) | Polimeros colorantes cationicos | |
| MX374694B (es) | USO DE 1-CLORO-4-(ß-D-GLUCOPIRANOS-1-IL)-2-[4-((S)-TETRAHIDROFURAN-3-ILOXI)-BENCIL]-BENCENO EN COMBINACIÓN CON INSULINA PARA REDUCIR LA DOSIS DE INSULINA Y PARA MEJORAR EL CONTROL GLUCÉMICO EN PACIENTES CON DIABETES MELLITUS. | |
| JP2014501485A5 (enExample) | ||
| EP2938273A4 (en) | WUNDKLAMMERPATRONE WITH IMPROVED KNIFE GAME | |
| CL2014003191A1 (es) | Compuestos que inhiben la actividad de catecol o -metiltransferasa; su uso contra el parkinson. | |
| BRPI0914069A2 (pt) | composição de vacina para uso contra o influenza | |
| DK2280605T3 (da) | Herbicide sammensætninger, der omfatter pyroxasulfon | |
| MX374468B (es) | Composicion farmaceutica acuosa semisolida que contiene tapentadol. | |
| CY1118976T1 (el) | Κρυσταλλικες τροποποιησεις της (1r,2r)-3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολης | |
| BRPI0916060A2 (pt) | "interconector para fluidos" | |
| CO6771459A2 (es) | Formulaciones que comprenden 2-amino-2-[2- (4-octil-fenil)-etil] -propano-1,3-diol | |
| BR112012024357A2 (pt) | processo para a produção de borrachas de nitrila hidrogenada livre de solvente e água | |
| PA8814801A1 (es) | Triazolopiridazinas como inhibidores de par1, su preparación y su uso como medicamentos | |
| CL2011000100A1 (es) | Uso de un inhibidor de desacetilasa de histona para el tratamiento de la enfermedad de hodgkin. |